

Swiss pharmaceutical group Roche on Wednesday announced that it
had agreed to buy the US medical diagnostics company BioVeris
Corporation for 600 million dollars (449 million euros).


Roche will pay 21.5 dollars per share to buy all stock in the
Maryland-based firm under the deal, the Swiss company said in a
statement.


"The boards of directors of BioVeris and Roche have each
unanimously approved the terms of the merger agreement, and the
board of directors of BioVeris has recommended that its
shareholders approve the transaction," it added.


BioVeris develops immunochemistry technologies for diagnostics
and vaccine preparation.

